| 摘要 |
<p>The present invention relates to antitumor compounds of formula (I) wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of ε-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin or an epirubicin derivative.</p> |
